Valitor Inc. has presented preclinical results on VLTR-559, its long-acting anti-VEGF biologic candidate for durable wet age-related macular degeneration (AMD). VLTR-559, developed using Valitor’s proprietary Multivalent Polymer (MVP) technology, demonstrated prolonged ocular retention and maintained high potency even after months in ocular tissues.